human vcan elisa kit (Novus Biologicals)
Novus Biologicals is a verified supplier 
Novus Biologicals manufactures this product 
94
Structured Review
Novus Biologicals
human vcan elisa kit
Human Vcan Elisa Kit, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vcan+elisa+kit/pmc13130687-76-0-5?v=Novus+Biologicals
Average 94 stars, based on 2 article reviews
Human Vcan Elisa Kit, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vcan+elisa+kit/pmc13130687-76-0-5?v=Novus+Biologicals
Average 94 stars, based on 2 article reviews
human vcan elisa kit - by Bioz Stars,
2026-07
94/100 stars
Images
1) Product Images from "Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature"
Article Title: Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature
Journal: Cell Reports Medicine
doi: 10.1016/j.xcrm.2026.102694
Figure Legend Snippet: Graphical summary of the study In the Discovery phase, a 4-protein biomarker panel (THBS1, NID1, PTX3, and VCAN) was discovered by proteomic analysis of sEVs derived from an isogenic HBEC model using mass spectrometry. The biomarker panel was tested in sEVs isolated from 22 cancer cell lines by ELISA. In the Validation phase, a cohort consisting of 250 healthy individuals and 514 patients with multiple cancers was recruited to assess the performance of the biomarker panel. Plasma/serum sEVs were isolated and analyzed by ELISA. In the Translation phase, a multiplex microfluidic device incorporating SERS was developed for simultaneous profiling of the 4-protein biomarker panel in a lung cancer screening setting. The expression levels of 4 proteins are reflected by the Raman intensities of the corresponding Raman reporters.
Techniques Used: Biomarker Discovery, Derivative Assay, Mass Spectrometry, Isolation, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Multiplex Assay, Expressing
![Transformation-induced changes to the protein composition of cell-derived sEVs (A) The morphology of isolated sEVs was assessed using transmission electron microscopy. Images of normal and transformed HBEC-derived sEVs (scale bars, 200 nm). (B) Nanoparticle analysis using tunable resistive pulse sensing of sEVs isolated from HBECs demonstrates that the majority of sEVs have a size range between 30 and 150 nm, and that transformation does not result in an increase in sEV secretion. (C) Western blot of sEVs from HBECs demonstrating the presence of sEV proteins HSP70 and CD63 and the absence of the cell marker calnexin. (D) Label-free mass spectrometry identified 148 proteins with greater abundance in sEVs derived from transformed HBECs (FDR <0.02), of which 15 were annotated as extracellular proteins. (E) Mass spectrometry results were confirmed using ELISA for THBS1, NID1, PTX3, and VCAN in sEVs derived from normal and transformed HBECs. (F) sEVs derived from 22 cancer cell lines including NSCLC (SKMES1, H1650, HCC4006, and H2170), glioblastoma ([GBM], D54, D270, U87, and U118), colorectal cancer ([CRC], HT29 and SW620), breast cancer ([BCa], BT549, MDA231, and MDA436), prostate cancer ([PCa], PC3 and LNCaP), melanoma ([MEL], A375, MAMEL65, and SKMEL28), esophageal cancer ([ECa], OE19), and ovarian cancer ([OVA], A2780, CAOV3, IGROV1, and OVCAR8) showed a clear increase in expression of THBS1, NID1, PTX3, and VCAN in relation to the average levels of sEVs from normal cells ([HBEC] 30KT, HOSE 6.3, and HOSE 17.1). Samples in mass spectrometry and ELISA were measured in triplicate. See also and .](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0687/pmc13130687/pmc13130687__gr2.jpg "... confirmed using ELISA for THBS1, NID1, PTX3, and VCAN in sEVs derived from normal and transformed HBECs. ...")
Figure Legend Snippet: Transformation-induced changes to the protein composition of cell-derived sEVs (A) The morphology of isolated sEVs was assessed using transmission electron microscopy. Images of normal and transformed HBEC-derived sEVs (scale bars, 200 nm). (B) Nanoparticle analysis using tunable resistive pulse sensing of sEVs isolated from HBECs demonstrates that the majority of sEVs have a size range between 30 and 150 nm, and that transformation does not result in an increase in sEV secretion. (C) Western blot of sEVs from HBECs demonstrating the presence of sEV proteins HSP70 and CD63 and the absence of the cell marker calnexin. (D) Label-free mass spectrometry identified 148 proteins with greater abundance in sEVs derived from transformed HBECs (FDR <0.02), of which 15 were annotated as extracellular proteins. (E) Mass spectrometry results were confirmed using ELISA for THBS1, NID1, PTX3, and VCAN in sEVs derived from normal and transformed HBECs. (F) sEVs derived from 22 cancer cell lines including NSCLC (SKMES1, H1650, HCC4006, and H2170), glioblastoma ([GBM], D54, D270, U87, and U118), colorectal cancer ([CRC], HT29 and SW620), breast cancer ([BCa], BT549, MDA231, and MDA436), prostate cancer ([PCa], PC3 and LNCaP), melanoma ([MEL], A375, MAMEL65, and SKMEL28), esophageal cancer ([ECa], OE19), and ovarian cancer ([OVA], A2780, CAOV3, IGROV1, and OVCAR8) showed a clear increase in expression of THBS1, NID1, PTX3, and VCAN in relation to the average levels of sEVs from normal cells ([HBEC] 30KT, HOSE 6.3, and HOSE 17.1). Samples in mass spectrometry and ELISA were measured in triplicate. See also and .
Techniques Used: Transformation Assay, Derivative Assay, Isolation, Transmission Assay, Electron Microscopy, Tunable Resistive Pulse Sensing, Western Blot, Marker, Mass Spectrometry, Enzyme-linked Immunosorbent Assay, Expressing
![The transformed sEV signature accurately diagnoses cancer in patient plasma (A) The expression levels of THBS1, NID1, PTX3, and VCAN in plasma derived from cancer patients are increased in comparison to healthy controls. Samples were measured in triplicate. Lines in dot plots represent median values. (B) ROC curves of classification of each cancer type compared to healthy controls demonstrate excellent diagnostic capability of the 4-protein sEV biomarker panel with an AUC of 0.91–1. (C) The sensitivity of the diagnostic sEV signature for each cancer type was evaluated at a fixed specificity of 90%, 95%, and 99%. Error bars represent 95% confidence intervals. Healthy ( n = 250), NSCLC ( n = 139), glioblastoma ([GBM], n = 57), colorectal cancer ([CRC], n = 42), prostate cancer ([PCa], n = 30), melanoma ([MEL], n = 100), gastric cancer ([GCa], n = 19), esophageal cancer ([ECa], n = 98), small cell lung cancer ([SCLC], n = 29). See also and .](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0687/pmc13130687/pmc13130687__gr3.jpg "... The expression levels of THBS1, NID1, PTX3, and VCAN in plasma derived from cancer patients are increased ...")
Figure Legend Snippet: The transformed sEV signature accurately diagnoses cancer in patient plasma (A) The expression levels of THBS1, NID1, PTX3, and VCAN in plasma derived from cancer patients are increased in comparison to healthy controls. Samples were measured in triplicate. Lines in dot plots represent median values. (B) ROC curves of classification of each cancer type compared to healthy controls demonstrate excellent diagnostic capability of the 4-protein sEV biomarker panel with an AUC of 0.91–1. (C) The sensitivity of the diagnostic sEV signature for each cancer type was evaluated at a fixed specificity of 90%, 95%, and 99%. Error bars represent 95% confidence intervals. Healthy ( n = 250), NSCLC ( n = 139), glioblastoma ([GBM], n = 57), colorectal cancer ([CRC], n = 42), prostate cancer ([PCa], n = 30), melanoma ([MEL], n = 100), gastric cancer ([GCa], n = 19), esophageal cancer ([ECa], n = 98), small cell lung cancer ([SCLC], n = 29). See also and .
Techniques Used: Transformation Assay, Clinical Proteomics, Expressing, Derivative Assay, Comparison, Diagnostic Assay, Biomarker Discovery
Figure Legend Snippet: Evaluation of a multiplex microfluidic device applicable for liquid biopsy testing in a cancer screening setting (A) Clinical follow-up by CT imaging of 2 representative benign patients B1 and B2. Red arrows indicated nodules in patients’ lungs. B1 had a granuloma-cryptococcal infection, and the lesion was found less dense after 26 months. B2 had a lesion in the vicinity of emphysema, which resolved after 21 months. (B) Schematic of multiplex microfluidic device consisting of a pair of asymmetric circular electrodes. Electrodes are conjugated with an anti-THBS1 antibody to capture cancer-derived sEVs. SERS nanotags carrying designated Raman reporters and paired target antibodies (against THBS1, NID1, PTX3, and VCAN) are used for labeling captured sEVs and then analyzed by SERS mapping. (C) Representative false-color SERS spectral images demonstrating an enrichment of THBS1, NID1, PTX3, and VCAN in early-stage NSCLC patients (M1 and M2) compared to patients with benign diseases (B1 and B2). Scale bars, 10 μm. (D) The Raman intensity of each biomarker THBS1, NID1, PTX3, and VCAN in benign ( n = 27) and early-stage NSCLC ( n = 41) patients. a.u., arbitrary units. Samples were measured in triplicate. Lines in dot plots represent median values. (E) ROC curve of logistic regression classification indicating an AUC of 0.85 in detecting early-stage NSCLC cases compared to benign cases in a cancer screening setting. (F) The confusion matrix of the multiplex microfluidic device. See also and and .
Techniques Used: Multiplex Assay, Imaging, Infection, Derivative Assay, Labeling, Biomarker Discovery
Figure Legend Snippet: Evaluation of the multiplex microfluidic device in a longitudinally monitored cohort of pre- and post-surgery NSCLC patients (A) Representative false-color SERS spectral images demonstrating a decrease of THBS1, NID1, PTX3, and VCAN in post-surgery NSCLC patients (P2 post and P12 post) compared to paired pre-surgery (P2 pre and P12 pre) patients. Scale bars, 10 μm. (B) Heatmap showing the log 2 fold changes in Raman intensities of THBS1, NID1, PTX3, and VCAN in post-surgery NSCLC patients ( n = 12), relative to their paired pre-surgery samples. Samples were measured in triplicate. Negative values (blue) indicate decreased expression after surgery, while positive values (red) indicate increased expression. See also .
Techniques Used: Multiplex Assay, Expressing
